MYO earnings

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call star

Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decrease

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter of 2025 on Monday, November 10, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. T

Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025. Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated): Revenue was $9.7 million, up 28%; 56% of revenue was from Medicare Part B patients. Reven

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Th

Senior executives to provide an in-depth review of the Company's business model and discuss long-range aspirational financial metrics Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will host an Investor & Analyst Day event today from 10 a.m. to 3 p.m. Eastern time during which management will provide an in-depth review of the Company's business model, provide a tour of its new headquarters and manufacturing facility and discuss long-range aspirational financial metrics. A live and archived webcast of the event is available here. To be held

Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate

$9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Pro

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PI

Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2024. Financial and operational highlights for the second quarter of 2024 include the following (all comparisons are with the second quarter of 2023 unless otherwise indicated): Product revenue was $7.5 million, up 77%, with total revenue up 26% reflec

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2024 on August 6, 2024. The Company will host a conference call the same day, Tuesday August 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gai

Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2024. Financial and operational highlights for the first quarter of 2024 include the following (all comparisons are with the first quarter of 2023): Total

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call the same day, Wednesday May 8, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain im

Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year Record backlog of 230 patients as of December 31, 2023 Introduces 2024 first quarter and full year guidance Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023. Financial and operational h

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024. The Company will host a conference call the same day, Thursday March 7, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode an

Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2023. Financial and operational highlights for the third quarter of 2023 include the following (all comparisons are with the third quarter of 2022): Total revenue was $5.1

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023. The Company will host a conference call the same day, Tuesday November 7, 2023 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and u

Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid Services Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2023. Financial and operational highlights for the second quarter of 2023 include

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2023 on August 9, 2023. The Company will host a conference call the same day, Wednesday, August 9, 2023 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique P

Implementation of virtual waiting room technology enabled a record 438 patients added to the pipeline, up 54% over Q1 2022 Advertising efficiencies resulted in cost per pipeline add of $1,579, down 50% sequentially Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2023. Financial and operational highlights for the first quarter of 2023 include the following: Product revenue was $3.4 million, up 20% compared with

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023. The Company will host a conference call the same day, Wednesday, May 10, 2023 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain

Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference call begins at 10:00 a.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. Financial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.0 million, up 2% sequentially and similar to the prior year quarter; Reven

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market. The Company will host a conference call the same day, Monday, March 13, 2023 at 10:00 a.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given

Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2022. Financial and operational highlights for the third quarter of 2022 include the following: Product revenue was $4.0 million, up 8% sequentially; Revenue units were 87, up 9% sequentially; MyoPro orders and insurance

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close. The Company will host a conference call the same day, Thursday, November 10, 2022 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a

Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six months Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2022. Financial and operational highlights for the second quarter of 2022 include the following: Product revenue was $3.7 million, up 18% from Q2 2021 and up 28% sequentially; A record 420 new candidates were added to the patient pipel

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close. The Company will host a conference call the same day, Wednesday, August 3, 2022 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021. All revenue in the second quarter of 2022 was product revenue, as the Company did not receive payment of the remaining license fee from its joint venture partner in China. Also, Myomo expects to report more than 400 additions to its p

Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2022. Financial and operational highlights for the first quarter of 2022 include the following (all comparisons are with the first quarter of 2021, unless otherwise noted): Revenue was $3.9 million and includes $1.

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close. The Company will host a conference call the same day, Wednesday, May 11, 2022 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode an

Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2021. Financial and operational highlights for the fourth quarter of 2021 include the following (all comparisons are with the fourth quarter of 2020, unless otherwise noted)

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close. The Company will host a conference call the same day, Wednesday, March 9, 2022 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a c

Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 units Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2021. Financial and operational highlights for the third quarter of 2021 include the following (all comparisons are with the third quarter of 2020, unless otherwise noted): Revenue was $4.4 million

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2021 on November 10, 2021 after the market close. The Company will host a conference call the same day, Wednesday, November 10, 2021 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/101

 Revenue was $3.1 million, up 262% over prior year Gross margin was 71%, up 2,000 basis points over prior year Insurance authorizations and orders were a record 138 Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2021. Financial and operational highlights for the second quarter of 2021 include the following (all comparisons are with the second quarter of 2020, which was adversely impacted by the COVID-19 pand

Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2021 on August 9, 2021 after the market close. The Company will host a conference call the same day, Monday, August 9, 2021 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10158505/eaf8cf403